Last edition
News about "MAS treatment"
Atossa Therapeutics receives US Food and Drug Administration (FDA) Rare Pediatric Disease designation for (Z)-Endoxifen in McCune-Albright syndrome, qualifying for Priority Review Voucher award upon approval.
MAS Treatment | 05/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members